Condition: Colorectal Neoplasms · Chemotherapy Effect · Molecular Sequence Variation · Sponsor: City Clinical Oncology Hospital No 1
Patients meeting the inclusion criteria will be randomized 1:1 into Cohort A (n ≈ 177) or Cohort BC (n ≈ 177). Cohort A is the control: patients receive combination chemotherapy with FOLFOX plus anti-EGFR therapy (panitumumab or cetuximab) based on RAS/BRAF wild-type data, according to clinical guidelines. The BC cohort begins FOLFOX chemotherapy and simultaneously undergoes extensive molecular genetic profiling. Further, the BC cohort, depending on the profile, is divided into cohort B - patients without changes in alternative oncogenes, and cohort C - with changes in alternative oncogenes. The expected cohort ratio is 3:1 (\~120 and \~40 patients). Cohort B begins to receive anti-EGFR therapy in addition to chemotherapy, and the potentially resistant cohort C continues to receive chemotherapy alone or begins to receive bevacizumab if there are no contraindications.
This description comes directly from the study's public registry record.
Ilya Pokataev, phD · +74955369406 · pokia@mail.ru
Maria Byakhova, phD · +79151751299 · biakhovamm@mail.ru
Always discuss trial participation with your own doctor first.
| Moscow Multidiciplinary Clinical Center Kommunarka | Moscow, Russia | Recruiting |
| N.N Blokhin Cancer Reserch Center | Moscow, Russia | Recruiting |
| Reutov Clinical hospital | Reutov, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06226857